X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (633) 633
Publication (59) 59
Book Review (18) 18
Newsletter (18) 18
Newspaper Article (6) 6
Magazine Article (3) 3
Book Chapter (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fluconazole (460) 460
humans (435) 435
index medicus (312) 312
antifungal agents - therapeutic use (253) 253
female (170) 170
fluconazole - therapeutic use (151) 151
male (151) 151
adult (141) 141
microbiology (133) 133
antifungal agents (131) 131
pharmacology & pharmacy (131) 131
antifungal agents - economics (130) 130
infectious diseases (126) 126
epidemiology (118) 118
middle aged (118) 118
antifungal agents - pharmacology (115) 115
mycoses (105) 105
mortality (103) 103
itraconazole (100) 100
candidiasis (96) 96
health aspects (92) 92
aged (91) 91
fluconazole - economics (85) 85
infections (85) 85
voriconazole (80) 80
analysis (78) 78
research (77) 77
antifungal agents - administration & dosage (76) 76
mycology (76) 76
treatment outcome (71) 71
cost-benefit analysis (70) 70
drug therapy (70) 70
risk factors (69) 69
amphotericin-b (68) 68
retrospective studies (68) 68
prophylaxis (64) 64
therapy (63) 63
candidiasis - drug therapy (62) 62
fungal infections (62) 62
fluconazole - pharmacology (60) 60
microbial sensitivity tests (60) 60
mycoses - prevention & control (60) 60
amphotericin b (59) 59
mycoses - drug therapy (59) 59
risk-factors (59) 59
candidemia (57) 57
candida - drug effects (56) 56
fungi (55) 55
invasive candidiasis (55) 55
posaconazole (55) 55
fungal-infections (54) 54
candida (53) 53
care and treatment (53) 53
double-blind (53) 53
infection (53) 53
adolescent (52) 52
medicine & public health (52) 52
candida - isolation & purification (51) 51
research article (51) 51
amphotericin b - therapeutic use (48) 48
blood-stream infections (48) 48
animals (47) 47
dermatology (46) 46
itraconazole - therapeutic use (46) 46
liposomal amphotericin-b (46) 46
prevention (46) 46
aspergillosis (45) 45
diagnosis (45) 45
fluconazole - administration & dosage (44) 44
fungicides (43) 43
young adult (43) 43
antifungal agents - adverse effects (42) 42
medicine (42) 42
neutropenic patients (41) 41
antifungal prophylaxis (39) 39
drug resistance, fungal (39) 39
hospitals (39) 39
internal medicine (39) 39
invasive fungal-infections (39) 39
patients (39) 39
susceptibility (39) 39
yeast (39) 39
child (38) 38
medicine, general & internal (38) 38
administration, oral (37) 37
aged, 80 and over (37) 37
candidiasis - microbiology (37) 37
cost-effectiveness (37) 37
drug resistance (37) 37
triazoles - therapeutic use (37) 37
caspofungin (36) 36
resistance (36) 36
antifungal therapy (35) 35
fluconazole resistance (35) 35
immunology (35) 35
albicans (34) 34
dosage and administration (34) 34
management (34) 34
pharmacokinetics (34) 34
cancer (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (641) 641
French (8) 8
German (3) 3
Spanish (3) 3
Italian (2) 2
Japanese (2) 2
Russian (2) 2
Turkish (2) 2
Bulgarian (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 07/2017, Volume 17, Issue 1, pp. 481 - 9
Background: Cost-effectiveness studies of echinocandins for the treatment of invasive candidiasis, including candidemia, are rare in Asia. No study has... 
Echinocandin | Pharmacoeconomics | Antifungal therapy | Candidemia | Anidulafungin | Fluconazole | COST-EFFECTIVENESS ANALYSIS | CASPOFUNGIN | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | MANAGEMENT | GUIDELINE | RECOMMENDATIONS | EPIDEMIOLOGY | Candida albicans - pathogenicity | Economics, Pharmaceutical | Lipopeptides - therapeutic use | Humans | Treatment Outcome | Candidemia - mortality | Antifungal Agents - economics | Candidemia - economics | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Candidiasis, Invasive - mortality | Candida albicans - drug effects | Candida - pathogenicity | Candidemia - drug therapy | Candidiasis, Invasive - economics | Echinocandins - economics | Lipopeptides - economics | Cost-Benefit Analysis | Fluconazole - economics | Candidiasis, Invasive - drug therapy | Taiwan | Echinocandins - therapeutic use | Candida - drug effects | Economic aspects | Candidiasis | Dosage and administration | Research | Drug therapy | Antifungal agents | Health care | Intensive care | Fungicides | Medical services | Clinical trials | Infections | Epidemiology | Success | Clinical outcomes | Fungi | Caspofungin | Drug dosages | Economics | Medical research | Sensitivity analysis | Mortality | Acne | Health care policy | Pharmacology | Micafungin | Construction costs | Studies | Sensitivity | Infectious diseases | Hospitals | Echinocandins | Cost analysis
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 376 - 386
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69288
Objectives: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at... 
IMMUNODEFICIENCY-VIRUS-INFECTION | SUB-SAHARAN AFRICA | SYSTEMIC FUNGAL-INFECTIONS | FLUCONAZOLE PROPHYLAXIS | MULTIDISCIPLINARY SCIENCES | PRIMARY PROPHYLAXIS | DOUBLE-BLIND | OPPORTUNISTIC INFECTIONS | ANTIRETROVIRAL THERAPY | ITRACONAZOLE PROPHYLAXIS | PLACEBO-CONTROLLED TRIAL | Markov Chains | Meningitis, Cryptococcal - economics | Mass Screening - economics | Humans | Cryptococcus neoformans - immunology | AIDS-Related Opportunistic Infections - diagnosis | Antigens, Fungal - immunology | Models, Statistical | Patient Outcome Assessment | Meningitis, Cryptococcal - diagnosis | AIDS-Related Opportunistic Infections - economics | Health Care Costs | Cost-Benefit Analysis | South Africa | Prevention | Antigens | Antiviral agents | Fluconazole | Analysis | Mortality | Economic aspects | Meningitis | Cost benefit analysis | HIV (Viruses) | Health aspects | Therapy | Immunoassay | Prophylaxis | Central nervous system | Medical services | Infections | Drug resistance | Tropical diseases | Lipopolysaccharides | Health economics | Cost effectiveness | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Drug therapy | Drug dosages | Disease control | Patients | CD4 antigen | Disease prevention | Medicine | Screening | Infectious diseases | Strategy | Cost analysis | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Advances in Therapy, ISSN 0741-238X, 9/2017, Volume 34, Issue 9, pp. 2104 - 2119
Journal Article
European Journal of Haematology, ISSN 0902-4441, 2008, Volume 81, Issue 6, pp. 467 - 474
Background:  Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients experience prolonged neutropenia after treatment with intensive... 
posaconazole | fluconazole | prophylaxis | cost effectiveness | fungal infections | the Netherlands | The Netherlands | Fungal infections | Cost effectiveness | Fluconazole | Posaconazole | Prophylaxis | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | HEMATOLOGICAL MALIGNANCY | ANTIFUNGAL PROPHYLAXIS | RANDOMIZED-TRIAL | INVASIVE FUNGAL-INFECTIONS | CHRONIC MYELOID-LEUKEMIA | CONTROLLED-TRIALS | HEMATOLOGY | MARROW TRANSPLANTATION | Models, Econometric | Triazoles - administration & dosage | Humans | Middle Aged | Fluconazole - administration & dosage | Itraconazole - economics | Male | Myelodysplastic Syndromes - economics | Myelodysplastic Syndromes - therapy | Netherlands | Neutropenia - mortality | Triazoles - economics | Adult | Female | Itraconazole - administration & dosage | Leukemia, Myeloid, Acute - therapy | Mycoses - prevention & control | Costs and Cost Analysis | Mycoses - economics | Neutropenia - economics | Antifungal Agents - economics | Randomized Controlled Trials as Topic | Leukemia, Myeloid, Acute - mortality | Fluconazole - economics | Myelodysplastic Syndromes - mortality | Neutropenia - therapy | Aged | Leukemia, Myeloid, Acute - economics | Mycoses - mortality | Antifungal Agents - administration & dosage | Chemotherapy | Heterocyclic compounds | Leukemia | Mycoses | Medical economics | Standards | Cancer | Itraconazole
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 9, pp. 2019 - 2027
Abstract Purpose Posaconazole is effective for the prophylaxis of invasive fungal infections (IFIs) in patients with acute myeloid leukemia or myelodysplastic... 
Internal Medicine | Medical Education | posaconazole | cost–benefit analysis | antibiotic prophylaxis | acute myeloid leukemia | myelodysplastic syndromes | cost-benefit analysis | INFECTIONS | INVASIVE FUNGAL DISEASE | PREVENTION | NEUTROPENIC PATIENTS | ACUTE MYELOID-LEUKEMIA | CHEMOTHERAPY | ASPERGILLOSIS | DEFINITIONS | CLINICAL EFFECTIVENESS | PHARMACOLOGY & PHARMACY | EXPERIENCE | Drug Costs | Hospital Costs | Humans | Middle Aged | Itraconazole - economics | Male | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Antineoplastic Agents - adverse effects | Triazoles - economics | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Retrospective Studies | Republic of Korea | Triazoles - therapeutic use | Mycoses - prevention & control | Primary Prevention - economics | Antifungal Agents - economics | Remission Induction | Itraconazole - therapeutic use | Propensity Score | Cost-Benefit Analysis | Fluconazole - economics | Cost Savings - economics | Antibiotic Prophylaxis - economics | Mycoses - chemically induced | Chemotherapy | Fluconazole | Leukemia | Mycoses | Cost benefit analysis | Cancer | Itraconazole | Health insurance | Transplants & implants | Mortality | Neutrophils | Fungal infections | Cancer therapies | Cost control | Benefit cost analysis | Clinical outcomes | Studies | Hospitals | Pharmacy | Stem cells | Blood diseases | Neutropenia
Journal Article